SLC5A2 and kidney disorder: However, secondary analyses of randomized trials involving finerenone showed the additional benefits of introducing finerenone on top of sodium-glucose cotransporter 2 inhibitors About 7% of the FIDELITY population had concomitant use of sodium-glucose cotransporter 2 inhibitors (Table 1), and the hazard ratios for the composite endpoint of kidney disease were 0.80 (95% CI 0.69–0.92) without sodium-glucose cotransporter 2 inhibitors and 0.42 (95% CI 0.16–1.08) with sodium-glucose cotransporter 2 inhibitors [23].